Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma. Academic Article uri icon


  • Glioblastoma (GBM) is among the most common and malignant types of primary brain tumors in adults, with a dismal prognosis. Although alkylating agents such as temozolomide are widely applied as the first-line treatment for GBM, they often cause chemoresistance and remain ineffective with recurrent GBM. Alternative therapeutics against GBM are urgently needed in the clinic. We report herein the discovery of a class of inhibitors (YZ129 and its derivatives) of the calcineurin-NFAT pathway that exhibited potent anti-tumor activity against GBM. YZ129-induced GBM cell-cycle arrest at the G2/M phase promoted apoptosis and inhibited tumor cell proliferation and migration. At the molecular level, YZ129 directly engaged HSP90 to antagonize its chaperoning effect on calcineurin to abrogate NFAT nuclear translocation, and also suppressed other proto-oncogenic pathways including hypoxia, glycolysis, and the PI3K/AKT/mTOR signaling axis. Our data highlight the potential for targeting the cancer-promoting HSP90 chaperone network to treat GBM.

published proceedings

  • Cell Chem Biol

altmetric score

  • 12.83

author list (cited authors)

  • Liu, Z., Li, H., He, L., Xiang, Y. u., Tian, C., Li, C., ... Zhou, Y.

citation count

  • 16

complete list of authors

  • Liu, Zhenzhen||Li, Hongli||He, Lian||Xiang, Yu||Tian, Chengsen||Li, Can||Tan, Peng||Jing, Ji||Tian, Yanpin||Du, Lupei||Huang, Yun||Han, Leng||Li, Minyong||Zhou, Yubin

publication date

  • March 2019